Part 8/13:
A major concern raised is the financial motivations behind transgender treatments. Myers explains that pharmaceutical companies have projected a $2 billion industry in transgender-related healthcare. The use of puberty blockers and cross-sex hormones, initially drugs approved for other purposes (such as prostate cancer or endometriosis), has become a profitable avenue—selling treatments that generate millions of dollars annually.